Quantcast
Home > Quotes > ERYP
ERYP

Erytech Pharma S.A. American Depositary Shares (ERYP) Quote & Summary Data

$21.41
*  
0.72
3.48%
Get ERYP Alerts
*Delayed - data as of Apr. 19, 2018  -  Find a broker to begin trading ERYP now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    ERYP Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
45.5
Today's High / Low
$ 21.41 / $ 21.41
Share Volume
150
50 Day Avg. Daily Volume
606
Previous Close
$ 20.69
52 Week High / Low
$ 30.56 / $ 17.50
Market Cap
384,042,624
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.81

Intraday Chart

Shares Traded

Share Volume:
150
50 Day Avg. Daily Volume:
606

Trading Range

The current last sale of $21.41 is 22.34% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 21.41 $ 30.56
 Low: $ 21.41 $ 17.50

Company Description (as filed with the SEC)

We are a biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting both solid and liquid tumors for patients with high unmet medical needs. Our lead product candidate, which we refer to as eryaspase or GRASPA, targets the metabolism of cancers by depriving tumor cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. We are developing eryaspase for the treatment of solid tumors, including pancreatic cancer. Based on the initial feedback we received from the U.S.  ... More ...  

Risk Grade

Where does ERYP fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
N/A
Open Date:
N/A
Close Price:
N/A
Close Date:
N/A

Consensus Recommendation

Analyst Info